Atjaunināt sīkdatņu piekrišanu

Prostate Cancer Screening [Multiple-component retail product]

Edited by , Edited by , Edited by
  • Formāts: Multiple-component retail product, 328 pages, height x width: 229x152 mm, weight: 658 g, 58 black & white illustrations, 18 black & white halftones, 40 black & white line drawings
  • Sērija : Current Clinical Urology
  • Izdošanas datums: 01-Jun-2001
  • Izdevniecība: Humana Press Inc.
  • ISBN-10: 0896039013
  • ISBN-13: 9780896039018
Citas grāmatas par šo tēmu:
  • Multiple-component retail product
  • Cena: 107,99 €*
  • * Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena
  • Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena.
  • Daudzums:
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
Prostate Cancer ScreeningPalielināt
  • Formāts: Multiple-component retail product, 328 pages, height x width: 229x152 mm, weight: 658 g, 58 black & white illustrations, 18 black & white halftones, 40 black & white line drawings
  • Sērija : Current Clinical Urology
  • Izdošanas datums: 01-Jun-2001
  • Izdevniecība: Humana Press Inc.
  • ISBN-10: 0896039013
  • ISBN-13: 9780896039018
Citas grāmatas par šo tēmu:
Permanent link: https://www.kriso.lv/db/9780896039018.html
Keywords:
More than one in six men will develop prostate cancer in their lifetime. In recent years there has been an explosion of information regarding PSA screening and biomarkers for the disease. In "Prostate Cancer Screening, Second Edition", the world's leading experts on prostate cancer detection update the first edition with the latest findings. The book incorporates a series of thoughtful and cutting-edge works from the world's experts in prostate cancer screening, ranging from the current status quo of prostate cancer screening across the globe to consensus on optimal utilization of the traditional PSA and DRE tests, to cutting-edge research in new biomarkers, biomeasures, and extended risk algorithms for prostate cancer.An additional chapter covers family-based linkage analysis as well as possible pitfalls in prostate cancer biomarker evaluation studies. Timely and authoritative, "Prostate Cancer Screening, Second Edition", is an essential text for urologists, oncologists and family physicians, as well as researchers in the biomarker industry who seek methods to better develop and support markers and measures of prostate cancer.

Recenzijas

This book describes in depth the current status of PSA screening as well as other diagnostic tools. The book also includes a compact disk with a program that can calculate risk of developing prostate cancer. The book is well written and readable, not only for the specialist, but also the interested physician, trainee or student. - Oncology "...offers valuable background information for urologists and family physicians" - Clinical Chemistry Comprehensive and balanced, Prostate Cancer Screening, presents a lively and rigorous evaluation of the science of prostate cancer screening, affording the health care provider with an informative discussion of its pros and cons, together with user-friendly computer program that analyzes an individual patient's risk of prostate cancer. - Tumori

Preface v List of Contributors ix Epidemiology of Prostate Cancer 1(24) Wael A. Sakr Clara Ward Natural History of Prostate Cancer 25(22) Peter C. Albertsen Mathematical Issues: PSA Testing 47(16) Ruth Etzioni David F. Penson Evidence of Benefit of Screening in Other Cancers 63(16) Ismail Jatoi The Role of Prostate Specific Antigen and Its Variants in Prostate Cancer Screening 79(12) Faiyaaz M. Jhaveri Michael K. Brawer Eric A. Klein The Digital Rectal Examination in Prostate Cancer Screening 91(6) Joseph Basler Philosophical Reflections on PSA Screening: What Should We Now Think and Do? 97(8) Paul H. Lange Imaging in Prostate Cancer Screening 105(26) Aaron Sulman Martin I. Resnick Risk Factors for Prostate Cancer 131(16) David L. Shepherd Transrectal Ultrasound and Artificial Neural Networks in the Diagnosis of Prostate Cancer 147(10) Tillmann Loch Evidence of the Effectiveness of Prostate Cancer Screening 157(18) Chris Magee Ian M. Thompson Prostate Cancer Screening: A Note of Caution 175(12) Otis W. Brawley Quality of Life and Health Behavior in Prostate Cancer Screening Populations 187(22) Mark S. Litwin Kristen A. Reid Prostate Cancer Screening Recommendations from Organized Medicine 209(14) Gregory T. Sweat Informed Consent and Prostate Specific Antigen Screening: What Patients Ought to Know 223(16) Evelyn C. Y. Chan Experience of Prostate Cancer Awareness Week 239(16) Zinelabidine Abouelfadel E. David Crawford The Laval University Screening Trial Results 255(26) Fernand Labrie Bernard Candas Lionel Cusan Jose-Luis Gomez Cancer of the Prostate Risk Index Test and Software (CAPRI) (CAPRI Software on Attached CD ROM) 281(10) Scott A. Optenberg Atanacio C. Guillen John P. Campbell Ian M. Thompson The European Randomized Study of Screening for Prostate Cancer (ERSPC) 291(20) Fritz H. Schroder Ingrid van der Cruijsen-Koeter Index 311